



Application No. 10/532,320
Paper dated November 2, 2006
Attorney Docket No. 0470-051244

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/532,320
Applicants : Herman Jan Tijmen Coelingh Bennink et al.
Filed : June 2, 2006
Title : Pharmaceutical Compositions Comprising Estetrol Derivatives For Use In Cancer Therapy
Group Art Unit : 1614
Examiner : Not Yet Assigned
Confirmation No. : 9143
Customer No. : 28989

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits this Information Disclosure Statement together with a completed Form PTO/SB/08A and a copy of the foreign patent documents and articles listed thereon. The cited U.S. patents are not enclosed pursuant to the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for U.S. national patent applications filed after June 30, 2003.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 2, 2006.

Bruce L. White
(Name of Person Mailing Paper or Fee)

Bruce L. White 11/02/2006
Signature Date

Application No. 10/532,320
Paper dated November 2, 2006
Attorney Docket No. 0470-051244


This application is the United States national phase of PCT Application No. PCT/NL03/00718. The references listed on Form PTO/SB/08A were identified by the International Search Report dated February 20, 2004 for the underlying PCT Application or were identified and cited in the specification of the application by the Applicants. A copy of the International Search Report is enclosed for the Examiner's convenience.

Pursuant to 37 C.F.R. § 1.97(b)3, no fee is believed to be due for the submission of this Information Disclosure Statement, as it is being submitted before the mailing date of a first Office Action on the merits. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.


Respectfully submitted,

THE WEBB LAW FIRM

By


William H. Logsdon
Registration No. 22,152
Attorney for Applicant
700 Koppers Building
436 Seventh Avenue
Pittsburgh, Pennsylvania 15219
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				<i>Complete if Known</i>
				Application Number 10/532,320
				Filing Date June 2, 2006
				First Named Inventor Herman Jan Tijmen Coelingh Bennink
				Art Unit 1614
				Examiner Name Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number 0470-051244

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 4,937,238	06/26/1990	Lemon	
		US- 5,340,584	08/23/1994	Spicer et al.	
		US- 5,340,585	08/23/1994	Pike et al.	
		US- 5,468,736	11/21/19985	Hodgen	
		US- 2003/0203933 A1	10/30/2003	Lee et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 1 120 114 A2	08/01/2001	Thompson et al.		
		WO 93/09771	05/27/1993	Stupak et al.		
		WO 94/26207	11/24/1994	Pike		
		WO 95/17895	07/06/1995	Goddar et al.		
		WO 00/73416 A1	12/07/2000	Labarbera et al.		
		WO 01/32683 A1	05/10/2001	Slemon		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

<i>Complete if Known</i>	
Application Number	10/532,320
Filing Date	June 2, 2006
First Named Inventor	Herman Jan Tijmen Coelingh Bennink
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	0470-051244

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CUSHING et al., Risk of Endometrial Cancer in Relation to Use of Low-Dose, Unopposed Estrogens, Estrogen and Endometrial Cancer, January 1998, pp. 35-39, Vol. 91, No. 1	
		TAVANI et al., The Adverse Effects of Hormone Replacement Therapy, Drugs & Aging, May 14, 1999, pp. 347-357, Vol. 5	
		PIKE et al., Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer, Steroids, 2000, pp. 659-664, Vol. 65	
		BERAL et al., Use of HRT and the subsequent risk of cancer, Journal of Epidemiology and Biostatistics, 1999, pp. 191-215, Vol. 4, No. 3	
		TULCHINSKY et al., Plasma Estetrol as an Index of Fetal Well-being, JCE & M, 1075, pp. 560-567, Vol. 40, No. 4	
		LEVINE, et al., Uterine vascular effects of estetrol in nonpregnant ewes, Am. J. Obstet. Gynecol., March 15, 1984, pp. 735-738	
		JOZAN et al., Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells, Acta Endocrinologica, 1981, pp. 73-80,	
		TSENG et al., Heterogeneity Of Saturable Estradiol Binding Sites In Nuclei Of Human Endometrium Estetrol Studies, Departments of Obstetrics and Gynecology, State University of New York at Stony Brook, Stony Brook, NY, USA and Mount Sinai School of Medicine, New York, NY, March 1978, pp. 1145-1148	
		MARTUCCI et al., Direction of Estradiol Metabolism as a Control of its Hormonal Action – Uterotrophic Activity of Estradiol Metabolites, Institute for Steroid Research, Montefiore Hospital and Medical Center, and Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, May 13, 1977, pp. 1709-1714	
		MURPHY et al., Endometrial effects of long-term low-dose administration of RU486, Fertility And Sterility, April 1995, pp. 761-766, Vol. 63, No. 4	
		ALLEN et al., An Ovarian Hormone Preliminary Report On Its Localization, Extraction And Partial Purification And Action In Test Animals, Jour. A. M. A., September 8, 1923, pp. 819-821, Vol. 81, No. 10	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	4	Attorney Docket Number	0470-051244
-------	---	----	---	------------------------	-------------

Complete if Known

Application Number	10/532,320
Filing Date	June 2, 2006
First Named Inventor	Herman Jan Tijmen Coelingh Bennink
Art Unit	1614
Examiner Name	Not Yet Assigned

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALLEN et al., The Induction Of A Sexually Mature Condition In Immature Females By Injection Of The Ovarian Follicular Hormone, Washington University School of Medicine, Saint Louis, The Department of Anatomy, University of Missouri, and The Laboratories of Biological Chemistry, Saint Louis University School of Medicine, May 16, 1924, pp. 577-587	
		JONES, M.S. et al., The Effects Of Various Steroids On The Vaginal Histology In The Rat, Fertility And Sterility, April 1973, pp. 284-291, Vol. 24, No. 4	
		REEL et al., Survey and Assessment of Mammalian Estrogen Biological Assays for Hazard Characterization, Fundamental And Applied Toxicology, 1996, pp. 288-305, Vol. 34	
		KUIPERS et al., Enterohepatic Circulation in the Rat, Gastroenterology, 1985, pp. 403-411, Vol. 88	
		AVVAKUMOV et al., Steroid-binding Specificity of Human Sex Hormone-binding Globulin Is Influenced by Occupancy of a Zinc-binding Site, The Journal Of Biological Chemistry, 2000, pp. 25920-25925, Vol. 275, No. 34	
		ELGER et al., Sulfamates of Various Estrogens are Prodrugs with Increased Systemic and Reduced Hepatic Estrogenicity at Oral Application, J. Steroid Biochem. Molec. Biol., 1995, pp. 395-403, Vol. 55, No. ¾	
		HAMMOND et al., A versatile method for the determination of serum cortisol binding globulin and sex hormone binding globulin binding capacities, Clinica Chimica Acta, 1983, pp. 101-110, Vol. 132	
		MUECK et al., Angiogenetic and Anti-Angiogenetic Effects of Estradiol and its Metabolites, J. Clin. Basic Cardiol., 2001, pp. 153-156, Vol. 4	
		LIPPERT et al., The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells, Life Sciences, 2000, pp. 1653-1658, Vol. 67	
		COFFEY et al., Similarities Of Prostate And Breast Cancer: Evolution, Diet, and Estrogens, XP-001027445, Elsevier Science, Inc., 2001	
		MOBBS et al., Suppression Of The Growth Of The Androgen-Insensitive R3327 Hi Rat Prostatic Carcinoma By Combined Estrogen And Antiprogestin Treatment, Steroid Biochem. Molec. Biol., 1991, pp. 713-722, Vol. 39, No. 5A	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

{W0310850.1}

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Attorney Docket Number 0470-051244

Complete if Known

Application Number	10/532,320
Filing Date	June 2, 2006
First Named Inventor	Herman Jan Tijmen Coelingh Bennink
Art Unit	1614
Examiner Name	Not Yet Assigned

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARTUCCI et al., Uterine Estrogen Receptor Binding Of Catecholestrogens And Of Estetrol (1, 3, 5(10) – Estratriene-3, 15 α , 16 α , 17 β -Tetrol), Institute for Steroid Research and Department of Oncology and Biochemistry, Montefiore Hospital and Medical Center, Albert Einstein College of Medicine, Bronx, NY, November 8, 1975, pp. 325-333, Vol. 27, No. 3	
		TSENG et al., Competition Of Estetrol And Ethynodiol-Di醋酸 With Estradiol For Nuclear Binding In Human Endometrium, Journal of Steroid Biochemistry, 1976, pp. 817-822, Vol. 7	
		HOLINKA et al., In vivo Effects of Estetrol on the Immature Rat Uterus, Biology Of Reproduction, 1979, pp. 242-246, Vol. 20	
		HOLINKA et al., Comparison of Effects of Estetrol and Tamoxifen with Those of Estriol and Estradiol on the Immature Rat Uterus, Biology of Reproduction, 1980, pp. 913-926, Vol. 22	
		LOPEZ-OTIN et al., Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features, Endocrine Reviews, August 1998, pp. 365-396, Vol. 19, No. 4	
		KUHNEL et al., Androgen Dependency Of Human Ovarian Cancer May Be Due To A Para Or Autocrine Action, XP-009025474, Abstracts of the First International Conference of Anticancer Research, October 26-30, 1985, p. 603	
		RAJ et al., Pineal-Thyroid Relationship in Breast Cancer, XP-009025474, Abstracts of the First International Conference of Anticancer Research, October 26-30, 1985, p. 603	
		ALVARADO-PISANI et al., Thyroid Hormone Receptors In Human Breast Cancer: Effect Of The Thyroxine Administration And Interrelation With Sex Hormone Axis, XP-009025474, Abstracts of the First International Conference of Anticancer Research, October 26-30, 1985, p. 603	
		CORBISHLEY et al., Androgen Receptor In Human Normal And Malignant Pancreas And Cell Lines, XP-009025474, Abstracts of the First International Conference of Anticancer Research, October 26-30, 1985, p. 603	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.